MediPharm Labs Announces Leadership Change As CEO David Pidduck Steps Down; CFO Greg Hunter Appointed Interim CEO

MediPharm Labs Corp., a pharmaceutical company focused on precision-based cannabinoids, has announced that David Pidduck will step down from his position as Chief Executive Officer on January 23, 2026. The Board of Directors has appointed Greg Hunter, the company’s current Chief Financial Officer, to serve as Interim CEO while the Board evaluates long-term leadership plans. During this transitional phase, Mr. Hunter will continue to fulfill his responsibilities as CFO.

During his tenure, Mr. Pidduck played an important role in stabilizing MediPharm and reshaping it for future growth. He oversaw major restructuring initiatives that strengthened the company’s financial foundation and improved profitability. A key accomplishment under his leadership was the successful integration of VIVO Cannabis Inc., which MediPharm acquired in April 2023. Although he is stepping down from his executive role, Mr. Pidduck will remain on the Board to support a smooth leadership transition.

The Board expressed confidence in appointing Mr. Hunter as Interim CEO. Since joining MediPharm as Chief Financial Officer in February 2021, he has led significant cost-reduction efforts and improved financial controls across the organization. He has also played a central role in shaping the company’s commercial strategy by collaborating with teams in sales, marketing, and product development. His contributions include optimizing pricing, strengthening customer programs, securing improved commercial terms, and ensuring that manufacturing and supply operations meet market needs. These efforts have resulted in stronger operational performance, better margins, and a more competitive position in the market.

Beyond his financial expertise, Mr. Hunter brings more than two decades of diverse commercial and operational experience. He has held cross-functional leadership roles at major global companies such as Johnson & Johnson and Baxter, as well as within private equity-backed organizations. His background includes work across finance, sales, marketing, and operations, giving him a well-rounded perspective that will be valuable as MediPharm continues to advance its strategic goals.

Chris Taves, Chair of the Board, thanked Mr. Pidduck for his meaningful contributions, noting that his leadership strengthened the company’s financial direction and helped guide MediPharm through difficult market conditions. He also expressed confidence in Mr. Hunter’s ability to lead the organization during this transition, highlighting his strong operational discipline, execution skills, and focus on sustainable growth.